Peer-Reviewed Articles

Google Scholar, 12,868 citations, h-index 58 (17 Feb, 2017)

  1. Leinenga G, Nisbet R, Götz J (2017) Perspective: Ultrasound as a treatment modality in neurodegenerative diseases, Med J Aust, in press (acc Feb 3, 2017) [IF 4.098]
  2. Hatch R, Wei Y, Xia D, Götz J (2017) Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment, Acta Neuropathol, in press (acc. Jan 9, 2017) [IF 11.360]
  3. Ahmed RM, Muireann I, van Eersel J, Ke YD, Voelkerling A, van der Hoven J, Tanaka K, Karl T, Krill JK, Piguet O, Götz J, Kiernan MC, Halliday GM, Hodges JR, Ittner LM (2017) Mouse models of frontotemporal dementia: improving the understanding of these models by using an approach based on clinical symptoms, Neurosci & Biobeh Reviews, in press (acc. Jan 6, 2017) [IF 8.802]
  4. Bodea L-G, van der Jeugd A, Evans HT, Ittner LM, Delerue F, Kril J, Halliday G, Hodges J, Kiernan MC, Götz J (2017) Accelerated aging exacerbates the pre-existing pathology in a tau transgenic mouse model, Aging Cell, in press (acc. Nov 30, 2016) [IF 6.340]
  5. Hatch R, Leinenga G, Götz J (2016) Scanning Ultrasound (SUS) causes no changes to neuronal excitability and prevents age-related reductions in hippocampal CA1 dendritic structure in wild-type mice, PLoS One 11 (10):e0164278, [IF 3.234]
  6. Brandt R, Götz J (2016) Editorial for Special Issue on 'Cytoskeletal proteins in health and neurodegenerative disease' (9 contributions, page 213-353), Brain Res Bull 126: 213-216 [IF 2.572]
  7. Wang Y-J, Jiao S-S, Shen L-L, Zhu C, Bu X-L, Liu Y-H, Liu C-H, Yao X-Q, Zhang L-L, Zhou H-D, Walker DG, Tan J, Götz J, Zhou X-F (2016) Brain-derived neurotrophic factor protects against neurodegeneration in a mouse model of human tauopathy, Transl Psych 6 (10):e907 [IF 5.620]
  8. Chai Ye Jin, Sierecki E, Tomatis VM, Gormal RS, Ariotti N, Giles N, Xia D, Götz J, Parton R, Collins BM, Gambin Y, Meunier FA (2016) Munc18-1 is a molecular chaperone for a-synuclein controlling its self-replicating aggregation, J Cell Biol 214: 705-718, [IF 9.834] (1 cit.)
  9. Baker S, Polanco JC, Götz J (2016) Extracellular vesicles containing transgenic tau accelerate tau pathology in ALZ17 mice but do not seed mature neurofibrillary tangles, J Alzheimers Dis 54(3): 1207-1217, [IF 3.920]
  10. Xia D, Gutmann JM, Götz J (2016) Mobility and subcellular localization of endogenous, gene-edited Tau differs from that of over-expressed human wild-type and P301L mutant Tau, Scientific Reports 6:29074, [IF 5.578]
  11. Matamales M, Götz J, Bertran-Gonzalez J (2016) Quantitative imaging of cholinergic interneurons reveals a distinctive spatial organization and a functional gradient of activity across the mouse striatum, PLoS One 11(6): e0157682, [IF 3.534]
  12. Anggono V, Tsai L-H, Götz J (2016) Editorial: Glutamate receptors in Alzheimer’s disease: Mechanisms and therapies (7 contributions, 98 pages), Neural Plast 2016:8256196, [IF 3.582]
  13. Shibuya K, Park SB, Geevasing N, Menon P, JHowells J, Simon, NG, Huynh W, Noto, Y, Götz J, Kril J, Ittner LM, Hodges J, Halliday G, Vucic S, Kiernan MC (2016), Motor cortical function determines prognosis in sporadic ALS, Neurology 87(5): 513-20, [IF 8.286]            
  14. Baker S, Götz J (2016) A local insult of okadaic acid in wild-type mice induces tau phosphorylation and protein aggregation in anatomically distinct brain regions, Acta Neuropathol Comm 4: 32, [IF N.A.] (3 cit.)
  15. Polanco JC, Scicluna BJ, Hill AF, Götz J (2016) Tau-containing exosomes derived from rTg4510 mice can seed endogenous tau aggregation although they lack important tau phospho-epitopes, J. Biol. Chem 214: 705-718, [IF 4.573] (6 cit.)
  16. Bodea L, Eckert A, Ittner LM, Piguet O, Götz J (2016) Tau Physiology and Pathomechanisms in Frontotemporal Lobar Degeneration, J Neurochem 138 Suppl 1:71-94, [IF 4.281] (2 cit.)
  17. Matamales M, Skrbis Z, Hatch RJ, Balleine BW, Götz J, Bertran-Gonzalez J (2016) Aging-related dysfunction of striatal cholinergic interneurons produces conflict in action selection, Neuron 90: 362-73 [Highlighted in Nature 532: 417, 2016], [IF 18.418] (4 cit.)
  18. Liu C, Song X, Nisbet R, Götz J (2016) Co-immunoprecipitation with tau isoform-specific antibodies reveals distinct protein interactions, and highlights a putative role for 2N tau in disease, J. Biol. Chem 291: 8173-88, [IF 4.573] (3 cit.)
  19. Leinenga G, Langton C, Nisbet R, Götz J (2016) Ultrasound treatments of neurological diseases - current status and emerging applications, Nature Rev Neurol 12:161-174, [IF 15.358] (4 cit.)

  22. Van der Jeugd A, Vermaecke B, Halliday GM, Staufenbiel M, Götz J (2016) Impulsivity, decreased social exploration, and executive dysfunction in a mouse model of frontotemporal dementia, Neurobiol Learn Mem, 130:34-43, [IF 3.652] (4 cit.)
  23. Grimm A, Biliouris EE, Lang UE, Götz J, Mensah-Nyagan AG, Eckert A (2016) Sex hormone-related neurosteroids differentially rescue bioenergetic deficits induced by amyloid-β or hyperphosphorylated tau protein, Cell Mol Life Sci. 73:201-215, [IF 5.856] (10 cit.)
  24. Burrell JR, Halliday G, Kril JJ, Ittner L, Götz J, Kiernan MC, Hodges JR (2016) The fronto-temporal dementia-motor neuron disease continuum, Lancet, 388(10047):919-31 (ePub 2015), [IF 45.217] (13 cit.)
  25. Polanco JC, Götz J (2015) No full admission for tau to the exclusive prion club yet (News & Views), EMBO J, 14: 2990-2, [IF 10.434] (2 cit.)
  26. Ittner LM, Halliday GM, Kril JJ, Götz J, Hodges JR, Kiernan MC (2015) FTD and ALS - translating mouse studies into clinical trials, Nature Rev Neurol 11: 360-366, [IF 18.418] (13 cit.)
  27. Leinenga G, Götz J (2015) Scanning ultrasound efficiently removes amyloid-β and restores memory in an Alzheimer's disease mouse model, Science Transl Med 11: 276ra33  [IF 15.843] (68 cit.)

    * Highlighted in Science 347: 1186-87, 2015 
    * Highlighted in Nature Rev Neurol 11: 247, 2015
    * ranked #37 worldwide
    * Image selected for Art in Neuroscience Exhibition Scientific American/Luke Hammond

  28. Xia D, Li C, Götz J (2015) Pseudophosphorylation of Tau at distinct epitopes or the presence of the P301L mutation targets the microtubule-associated protein Tau to dendritic spines, BBA-Mol Basis Dis. (Biochim Biophys Acta) 1852: 913-924, [IF 5.089] (15 cit.)
  29. Nisbet R, Polanco JC, Ittner LM, Götz J (2015) Tau aggregation and its interplay with amyloid-beta, Acta Neuropathologica 129:207-20, [IF 9.777] (44 cit.)
  30. Cummins NT, Götz J (2015) Dementia and neurodegeneration - Role of mitochondria in Alzheimer's disease, Austr. Biochem. 46, 4-7, [IF N.A.]         
  31. Baker S, Götz J (2015) What can we learn about cerebral multi-morbidity from animal models? (in: Series on Cerebral Multimorbidity), Alzheimer's Research & Therapy 7:11, [IF 3.500] (1 cit.)
  32. Ittner A, Bertz J, Götz J, Ittner LM (2015) Tau-targeted passive immunization modulates aspects of pathology in Tau transgenic mice, J Neurochem 132: 135-45, [IF 3.973] (13 cit.)
  33. Frost B, Götz J, Feany M (2015) Connecting the dots between tau dysfunction and neurodegeneration, Trends Cell Biol 25: 46-53, [IF 12.314] (50 cit.)
  34. Chew Y, Götz J, Nicholas HR (2015) Neuronal protein with tau-like repeats PTL-1 regulates intestinal SKN-1 relocalisation in response to oxidative stress, Aging Cell 14: 148-51, [IF 6.340] (5 cit.)         
  35. Eckert A, Nisbet R, Grimm A, Götz J (2014) March separate, strike together - Role of phosphorylated tau in mitochondrial dysfunction in Alzheimer’s disease, BBA-Mol Basis Dis. (Biochim Biophys Acta) 1842: 1258-66, [IF 5.211] (29 cit.)
  36. Lu J, Li T, He R, Bartlett PF, Götz J (2014) Visualizing the microtubule-associated protein tau in the nucleus, Sci China Life Sci., Special Issue: "From Brain Function to Therapy" 57: 422-31, [IF 2.024] (22 cit.)
  37. Chen J, Mengru S, Wang X, Lu J, Wei Y, Tan Y, Liu Y, Götz J, He R, Hua Q (2014) The herbal compound Geniposide rescues formaldehyde-induced apoptosis in N2a neuroblastoma cells, Sci China Life Sci., Special Issue: "From Brain Function to Therapy" 57: 412-21, [IF 2.024] (15 cit.)
  38. Xia D, Götz J (2014) Premature lethality, hyperactivity and aberrant phosphorylation in transgenic mice expressing a constitutively active form of Fyn, Frontiers Mol Neurosci, Research Topic: 'Kinase dysregulation in Alzheimer's disease' 7:40. doi: 10.3389/fnmol.2014.00040. eCollection 2014 [IF N.A.] (4 cit.)
  39. Köhler C, Dinekov M, Götz J (2014) Granulovacuolar degeneration and unfolded protein response in mouse models of tauopathy and Aβ amyloidosis, Neurobiology of Disease 71:169-79, [IF 5.202] (11 cit.)
  40. Ullrich M, Liang V, Chew YL, Banister S, Song X, Zhaw T, Kam H, Berger S, Kassiou M, Nicholas HR#, Götz J# (2014) Bio-orthogonal labelling as a tool to identify newly synthesized proteins in the roundworm C. elegans, Nature Protocols 9: 2237-55 (#equal contribution), [IF 7.782] (8 cit.)
  41. Chew YL, Fan X, Götz J, Nicholas HR (2014) Regulation of age-related structural integrity in neurons by protein with tau-like repeats (PTL-1) is cell autonomous, Scientific Reports 4: 5185, [IF 5.078] (6 cit.)
  42. Liang V, Ullrich M, Lam H, Chew YL, Banister S, Song X, Zaw T, Kassiou M, Götz J#, Nicholas HR# (2014) Altered proteostasis in aging and heat shock response in C. elegans revealed by analysis of the global and de novo synthesised proteome, Cell Mol Life Sci. 71: 3339-61 (#equal contribution), [IF 6.265] (23 cit.)
  43. Liu C, Götz J (2013) Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus, PLoS ONE 8 (12): e84849, [IF 3.534] (23 cit.)
  44. Morcinek K, Köhler C, Götz J, Schröder H (2013) Pattern of tau hyperphosphorylation and neurotransmitter markers in the brainstem of senescent tau filament forming transgenic mice, Brain Res 1497: 73-84 [IF 2.728] (2 cit.)
  45. Eckert A, Nisbet R, Grimm A, Götz J (2013) March separate, strike together - Role of phosphorylated tau in mitochondrial dysfunction in Alzheimer’s disease, BBA-Mol Basis Dis. (Biochim Biophys Acta) 1842: 1258-66, [IF 5.211] (33 cit.)
  46. Götz J, Lim Y-A, Eckert A (2013) Lessons from two prevalent amyloidoses - what amylin and Ab have in common, IN: Research topic: ‘Alzheimer’s disease and Type 2 Diabetes: Dissecting toxicity in conformational diseases’, Frontiers in Aging Neuroscience 5: 38, [IF 4.000] (16 cit.)
  47. Götz J, Xia D, Leinenga G, Chew YL, Nicholas H (2013) What renders tau toxic, IN: Topic title: Frontiers in Neurodegeneration, Research Topic: Tau oligomers, Frontiers Neurol, 4: 72, doi: 10.3389/fneur.2013.00072, [IF N.A.] (34 cit.)
  48. Chew YL, Fan X, Götz J, Nicholas HR (2013) Aging in the nervous system of Caenorhabditis elegans, Commun Integr Biol. 6:5, e25288, [IF N.A.] (1 cit.)
  49. Liu C, Götz J (2013) Inge Iqbal memorial: How it all started - tau and protein phosphatase 2A, J Alzheimers Dis 37: 483-94, [IF 3.612] (10 cit.)
  50. Delerue F, Sjollema G, Whittle B, Krüger S, Andrews D, Götz J (2013) Single nucleotide variants (SNVs) define senescence-accelerated SAMP8 mice, a model of a geriatric condition, J Alzheimers Dis 36: 325-35, [IF 3.612] (3 cit.)
  51. DuBoff B, Feany M, Götz J (2013) Why size matters - Balancing mitochondrial dynamics in Alzheimer's disease, Trends in Neurosciences 36: 325-335, [IF 12.902] (64 cit.)
  52. Chew YL, Fan X, Götz J, Nicholas HR (2013) Protein with tau-like repeats (PTL1) regulates neuronal integrity and lifespan in C. elegans, J Cell Sci 126: 2079-91, [IF 5.325] (23 cit.)
  53. Nilsen LH, Rae C, Ittner LM, Götz J, Sonnewald U (2013) Glutamate metabolism is impaired in transgenic mice with tau hyperphosphorylation, J Cereb Blood Flow Metab.  33: 684-91, [IF 5.339] (25 cit.)
  54. Köhler C, Dinekov M, Götz J (2013) Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice, Neurobiol Aging 34: 1369-79, [IF 4.853] (12 cit.)
  55. Schonrock N, Götz J (2012) Decoding the non-coding RNAs in Alzheimer's disease, Cell Mol Life Sci 69: 3543-59, [IF 5.856] (51 cit.)
  56. DuBoff B, Götz J, Feany M (2012) Tau promotes neurodegeneration via DRP1 mislocalization in vivo, Neuron 75: 618-32 [Highlighted by Cell leading Edge, Cell 151, 7-8, Sep 28, 2012], [IF 15.982] (110 cit.)
  57. Grimm A, Lim Y-A, Mensah-Nyagan AG, Götz J, Eckert A (2012) Alzheimer’s disease, oestrogen and mitochondria: An ambiguous relationship, Mol Neurobiol 46 (1): 151-60, [IF 5.286] (28 cit.)
  58. Lim Y-A, Giese M, Shepherd C, Halliday G, Kobayashi M, Takamatsu K, Staufenbiel M, Eckert A, Götz J (2012) Role of hippocalcin in mediating amyloid-beta toxicity, BBA-Mol Basis Dis, 1822 (8): 1247-57, [IF 5.089] (7 cit.)
  59. Ke Y, Dramiga Y, Schütz U, Ittner LM, Schröder H, Götz J (2012) Tau-mediated nuclear depletion of SFPQ in Alzheimer’s and Pick's disease, PLoS ONE 7(4):e35678 [selected for Faculty of 1000 Biology], [IF 3.534] (38 cit.)
  60. Khurana V, Merlo P, DuBoff B, Fulga TA, Sharp KA, Campbell S, Götz J, Feany MB (2012) A neuro-protectice role for the DNA damage checkpoint in tauopathy, Aging Cell 11 (2): 360-2, [IF 6.340] (16 cit.)
  61. Schmitt K, Grimm A, Kazmierczak A, Strosznajder J, Götz J, Eckert A (2012) Insights into mitochondrial dysfunction: aging, amyloid-beta and tau  - a deleterious trio, Antioxidants & Redox Signaling (ARS) 16 (12): 1456-66, [IF 7.667] (61 cit.)
  62. Schonrock, N, Humphreys D, Preiss T, Götz J (2012) Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-β, J Mol Neurosci 46: 324-35, [IF 2.757] (69 cit.)
  63. Schonrock N, Matamales M, Ittner LM, Götz J (2012) miRNA networks surrounding APP and amyloid-β metabolism – Implications for Alzheimer’s disease, Exp Neurol 235(2): 447-54, [IF 4.617] (63 cit.)
  64. Götz J, Ittner A, Ittner LM (2012), Tau-targeted treatment strategies in Alzheimer's disease, Brit J Pharmacol. 165(5): 1246-59, IF 4.990 (70 cit.)
  65. Götz J, Matamales M, Götz NN, Ittner LM, Eckert A (2012) Alzheimer’s disease models and functional genomics - How many needles are there in the haystack, IN: Topic Title: ‘From structural to molecular systems biology: experimental and computational approaches to unravel mechanisms of kinase activity regulation in cancer and neurodegeneration’, Front Physiol. 3:320, [IF N.A.] (18 cit.)
  66. Lim Y-A, Grimm A, Giese M, Mensah-Nyagan AG, Villafranca JE, Ittner LM, Eckert A, Götz J (2011) Inhibition of the mitochondrial enzyme ABAD restores the amyloid-β-mediated deregulation of estradiol, PLoS ONE 6(12):e28887, [IF 3.534] (28 cit.)
  67. Liu X, Dobbie M, Tunningley R, Whittle B, Zhang Y, Ittner LM, Götz J (2011) ENU mutagenesis screen to identify modifiers of a motor phenotype in tau mutant mice, J Biomed Biotechnol 130947 (doi: 10.1155/2011/130947), [IF 2.706] (7 cit.)
  68. Bi M, Ittner A, Ke Y, Götz J, Ittner LM (2011) Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic pR5 mice, PLoS ONE, 6(12):e26860, [IF 3.534] (91 cit.)
  69. Van Eersel J, Ke YD, Gladbach A, Bi M, Götz J, Kril JJ, Ittner LM (2011) Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons, PLoS ONE 6 (7): e22850 (Epub Jul 29, 2011), [IF 3.534] (43 cit.)
  70. Eckert A, Schmitt K, Götz J (2011), Mitochondrial dysfunction – the beginning of the end in Alzheimer’s disease? Separate and synergistic modes of tau and amyloid-beta toxicity, Alzheimer's Research & Therapy 3:15, [IF 3.500] (68 cit.)
  71. Götz J, Eckert A, Matamales M, Ittner LM, Liu X (2011), Modes of Aβ toxicity in Alzheimer’s disease, Cell Mol Life Sci. 68:3359-75, [IF 5.856] (78 cit.)
  72. Ittner A, Ke YD, van Eersel J, Gladbach A, Götz J, Ittner LM (2011), Brief update on different roles of tau in neurodegeneration, IUBMB Life 63:495-502, [IF 2.755] (40 cit.)
  73. Louis JV, Martens E, Borghgraef P, Lambrecht C, Longin S, Zwaenepoel K, Pijnenborg R, Landrieu I, Lippens G, Ledermann B, Götz J, Van Leuven F, Goris J, Janssens V (2011) Mice lacking phosphatase PP2A subunit PR61/B'δ (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3β, PNAS 108:6957-62, [IF 9.809] (46 cit.)
  74. Attems J, Ittner A, Jellinger K, Nitsch RM, Maj M, Wagner L, Götz J, Heikenwalder J (2011), Reduced secretagogin expression in the hippocampus of P301L tau transgenic mice, J Neural Transm 118:737-45, [IF 2.862] (11 cit.)
  75. Ittner LM, Götz J (2011) Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease, Nature Reviews Neurosci 12: 65-72 [reprinted in Nature 475:S23-S28][translated into German for: Spektrum der Wissenschaft], [IF 31.376] (570 cit.)
  76. Hundelt M, Fath T, Selle K, Oesterwind K, Jordan J, Schultz C, Götz J, von Engelhardt J, Monyer H, Lewejohann L, Sachser N, Bakota L, Brandt R (2011) Altered phosphorylation but no neurodegeneration in a mouse model of tau hyperphosphorylation, Neurobiol Aging 32:991-1006 (Epub 2009 Aug 5), [IF 4.853] (25 cit.)
  77. Pienaar IS, Götz J, Feany M (2010) Parkinson’s disease: insights from non-traditional model organisms, Prog. Neurobiol. 92: 558-71, [IF 10.301] (54 cit.)
  78. van Eersel, J, Ke YD, Liu X, Kril J, Götz J, Ittner LM (2010) Sodium selenate treatment mitigates tau pathology in Alzheimer’s disease models, PNAS 107: 13888-93, [IF 9.809] (129 cit.)
  79. Schonrock N, Ke YD, Humphreys D, Staufenbiel M, Ittner LM, Preiss T, Götz J (2010) Neuronal microRNA deregulation in response to Alzheimer’s disease amyloid-β, PLoS One 5(6): e11070. doi:10.1371/journal.pone.0011070, [IF 3.534] (128 cit.)
  80. Köhler C, Bista, P, Götz J, Schröder H (2010) Analysis of the cholinergic pathology in the P301L tau transgenic pR5 model of tauopathy, Brain Res 1347: 111-24 [IF 2.828] (5 cit.)
  81. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, Staufenbiel M, Hardeman E, Götz J (2010) Dendritic function of tau mediates amyloid- β toxicity in Alzheimer's disease mouse models, Cell 142: 387-397 [discussed in a Perspectives article: Haass C & Mandelkow E (2010) Fyn-Tau-amyloid: a toxic triad. Cell 142: 356-8] [Highlighted in Nature Rev Neurosci, Sep 2010] [Highlighted in Nature Biotechnology, Sep 2010][Selected for Faculty of 1000 Biology], [IF 33.116] (775 cit.)
  82. Krupka N, Strappe P, Götz J, Ittner LM (2010) Gateway compatible lentiviral transfer vectors for ubiquitin promoter driven expression of fluorescent fusion proteins, Plasmid 63: 155-60, [IF 1.760]  (13 cit.)
  83. Eckert A, Rhein V, Schulz KL, Götz J (2010) Convergence of amyloid-β and tau pathologies on mitochondria in vivo, Mol Neurobiol 41: 107-14, [IF 6.068]  (89 cit.)
  84. Lim Y-A, Rhein V, Baysang G, Meier F, Poljak A, Raftery M, Ittner LM, Guilhaus M, Eckert A, Götz J (2010) Aβ and human amylin share a common toxicity pathway via mitochondrial dysfunction, Proteomics 10: 1621-33, [IF 3.973] (76 cit.)
  85. Götz J, Lim Y-A, Ke YD, Eckert A, and Ittner LM (2010) Dissecting toxicity of tau and β-amyloid, Neurodeg Dis. 7:10-12, [IF 3.791] (17 cit.)
  86. Götz J, Gladbach A, Pennanen L, van Eersel J, Schild A, David D, Ittner LM (2010) Animal models reveal role for tau phosphorylation in human disease, BBA-Mol Basis Dis, Special issue on ‘Mouse Models of Human Neurological Disorders’ (BBADIS-09-30), 1802(10):860-71, [IF 5.089] (54 cit.)
  87. Ke YD, Delerue F, Gladbach A, Götz J, Ittner LM (2009) Experimental diabetes mellitus exacerbates the tau pathology in a transgenic mouse model of Alzheimer’s disease, PLoS ONE 4 (11): e7917, [IF 3.534] (125 cit.)
  88. Götz J, Götz NN (2009) Animal models for Alzheimer’s disease and frontotemporal dementia: a perspective, ASN Neuro 1(4). pii: e00019, [IF 4.436] (29 cit.)
  89. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Dröse S, Brandt U, Savaskan E, Czech C, Götz J, Eckert A (2009) Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice, PNAS 106: 20057-62. [Highlighted in Nature Rev Neurosci, Jan 2010], [IF 9.809] (328 cit.)
  90. Götz J (2009) Tiermodelle in der Alzheimerforschung, Gehirn & Geist, Spektrum der Wissenschaften, May issue, p. 54-59 [IF N.A.]
  91. Van Eersel J, Bi M, Ke YD, Hodges JR, Xuereb JH, Gregory GC, Halliday GM, Götz J, Kril JJ, Ittner LM (2009) Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains, J Neural Transm 116: 1243-51, [IF 2.862] (25 cit.)
  92. Ittner LM, Ke YD, Götz J (2009) Phosphorylated tau interacts with JNK interacting protein 1 (JIP1) in Alzheimer’s disease, J. Biol. Chem. 284: 20909-16, [IF 4.600] (92 cit.)
  93. Götz J, Ittner LM, Lim Y-A (2009) Common features between Diabetes mellitus and Alzheimer’s disease, Visions and Reflections, Cell Mol Life Sci. 66: 1321-5 plus Response to the comment 'Iron, type 2 diabetes mellitus, and Alzheimer's disease' to our Visions and Reflections article 'Common features between diabetes mellitus and Alzheimer's disease' Cell Mol Life Sci. 66: 2945, [IF 5.856] (106 cit.)
  94. Götz J, Schonrock N, Vissel B, Ittner LM (2009) Alzheimer’s disease selective vulnerability and modelling in transgenic mice, J Alzheimers Dis 18: 243-51, [IF 3.612] (25 cit.)
  95. Deters N, Ittner LM, Götz J (2009) Substrate-specific reduction of PP2A activity exaggerates tau pathology, Biochem. Biophys. Res. Commun. 379: 400-5, [IF 2,595] (35 cit.)
  96. Fath T, Ke YD, Gunning P, Götz J, Ittner LM (2009) Primary support cultures of hippocampal and substantia nigra neurons, Nature Protocols 4: 78-85, [IF 7.782] (87 cit.)
  97. Eckert A, Hauptmann S, Scherping I, Rhein V, Dröse S, Brandt U, Müller WE, Götz J (2008) Oligomeric and fibrillar species of β-amyloid (Aβ42) both impair mitochondrial function in P301L tau transgenic mice, J Mol Med 86: 1255-67 [selected for Faculty of 1000 Biology], [IF 4.739] (107 cit.) 
  98. Götz J, Ittner LM, Schonrock N, Cappai R (2008) An update on the toxicity of Aβ in Alzheimer’s disease, Neuropsych Dis and Treatm. 4: 1033-42, [IF N.A.] (41 cit.)
  99. Ittner LM, Fath T, Ke Y, Bi M, van Eersel J, Li KM, Gunning P, Götz J (2008) Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia, PNAS 105: 15997-16002, [IF 9.809] (123 cit.)
  100. Pienaar IS, Daniels WMU, Götz J (2008) Neuroproteomics as a promising tool in Parkinson’s disease research, J Neural Transm. 115: 1413-30, [IF 2.871] (22 cit.)
  101. Deters N, Ittner LM, Götz J (2008) Divergent phosphorylation pattern of tau in P301L tau transgenic mice, Eur. J. Neurosci. 28: 137-147, [IF 3.669] (52 cit.)
  102. Lim Y-A, Ittner LM, Lim YL, Götz J (2008) Human but not rat amylin shares neurotoxic properties with Aβ42 in long-term hippocampal and cortical cultures, FEBS Letters 582: 2188-2194 [cover image], [IF 3.341] (43 cit.)
  103. Baur K, Rauer M, Richter K, Pagenstecher A, Götz J, Hausmann J, Staeheli, P (2008) Antiviral CD8 T cells recognize Borna disease virus antigen transgenically expressed in either neurons or astrocytes, J. Virol. 82: 3099-3108, [IF 4.648] (15 cit.)
  104. Götz J, Ittner LM (2008) Animal models of Alzheimer’s disease and frontotemporal dementia, Nature Rev Neurosci 9: 532-544 [Featured article], [IF 31.376] (471 cit.) 
  105. Götz J, Ittner LM, Fändrich M, Schonrock N (2008) Is tau aggregation toxic or protective – a sensible question in the absence of sensitive methods?, J Alzheimers Dis 14(4): 423-429, [IF 3.612] (26 cit.)
  106. Götz J, David D, Hoerndli F, Ke YD, Schonrock N, Wiesner A, Fath T, Bokhari L, Lim Y-A, Deters N, and Ittner LM (2008) Functional Genomics dissects pathomechanisms in tauopathies: Mitosis failure and unfolded protein response, Neurodeg Dis. 5: 179-181, [IF 3.454] (9 cit.)
  107. Ittner LM, Schwerdtfeger K, Kunz TH, Muff R, Husmann K, Grimm C, Hafezi F, Lang KS, Kurrer MO, Götz J, Born W, Fischer JA (2008) Transgenic mice with ocular overexpression of an adrenomedullin receptor reflect human acute angle-closure glaucoma, Clinical Science 114(1): 49-58, [IF 5.629] (8 cit.)
  108. Eckert A, Hauptmann S, Scherping I, Rhein V, Müller-Spahn F, Götz J, Müller WE (2008) Soluble amyloid-beta leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice, Neurodeg Dis. 5: 157-9, [IF 3.454] (112 cit.)
  109. Hoerndli F, Pelech S, Papassotiropoulos, Götz J (2007) Aβ treatment and P301L tau expression in an Alzheimer’s disease tissue culture model act synergistically to promote aberrant cell cycle re-entry, Eur. J. Neurosci. 26(1): 60-72, [IF 3.669] (33 cit.)
  110. Götz J, Deters N, Doldissen A, Ke Y, Bokhari L, Wiesner A, Schonrock N, Ittner LM (2007) A decade of tau transgenic animal models and beyond, Brain Pathol., 17 (1): 91-103, [IF 4.354] (123 cit.)
  111. Ittner LM, Götz J (2007) Pronuclear injection for the production of transgenic mice, Nature Protocols 2(5): 1206-1215, [IF 7.782] (100 cit.)
  112. Habicht G, Haupt C, Friedrich RP, Hortschansky P, Sachse C, Meinhardt J, Wieligmann K, Gellermann G, Brodhuhn M, Götz J, Grigorieff N, Halbhuber K-J, Röcken C, Horn U, Fändrich M (2007) Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils, PNAS 104: 19232-19237, [IF 9.809] (176 cit.)
  113. Burke D, Hickie I, Breakspear M, Götz J (2007) Is there good news about dementia? Possibilities for the prevention and treatment of cognitive impairment and dementia, Brit. J. Psychiatry 190: 371-372, [IF 7.343] (24 cit.)
  114. Pei J-J, An W-L, Zhou X-W, Nishimura T, Norberg J, Benedikz E, Götz J, Winblad B (2006) P70S6 kinase mediates tau phosphorylation and synthesis, FEBS Letters 580: 107-114, [IF 3.341] (62 cit.)
  115. Tam CW, Husmann K, Clark NC, Clark JE, Lazar Z, Ittner LM, Götz J, Douglas G, Grant AD, Sugden D, Poston L, Poston R, McFadzean I, Marber MS, Fischer JA, Born W, Brain SD (2006) Enhanced vascular responses to adrenomedullin in mice overexpressing receptor activity-modifying protein 2., Circulation Res. 98: 262-70, [IF 11.089] (36 cit.)
  116. Kulic L, Kurosinski P, Chen F, Tracy J, Mohajeri MH, Li H, Nitsch RM, Götz J (2006) Active immunization trial in Aβ42-injected P301L tau transgenic mice, Neurobiology of Disease 22: 50-56, [IF 5.202] (19 cit.)
  117. Götz J, Ittner L, Kins S (2006) Do axonal defects in tau and APP transgenic animals model axonopathy in Alzheimer’s disease?, J. Neurochem. 98: 993-1006, [IF 4.244] (108 cit.)
  118. Götz J, Ittner LM, Schonrock N (2006) Alzheimer’s Disease and Frontotemporal Dementia – Prospects of a tailored therapy?, Med. J. Aust. 185: 381-384, [IF 3.789] (24 cit.)
  119. Schild A, Ittner LM, Götz J (2006) Altered phosphorylation of cytoskeletal proteins in mutant protein phosphatase 2A transgenic mice, Biochem. Biophys. Res. Commun. 343: 1171-1178, [IF 2,281] (27 cit.)
  120. Schild A, Isenmann S, Tanimoto N, Tonagel F, Seliger MW, Ittner LM, Kretz A, Ogris E, Götz J (2006) Impaired development of the Harderian gland in mutant protein phosphatase 2A transgenic mice, Mech. Dev. 123: 362-371, [IF 2.958] (15 cit.)
  121. David DC, Ittner LM, Gehrig P, Nergenau D, Shepherd C, Halliday G, Götz J (2006) β-Amyloid treatment of two complementary P301L tau-expressing Alzheimer’s disease models reveals similar deregulated cellular processes, Proteomics 6: 6566-6577, [IF 3.973] (69 cit.) 
  122. Pennanen L, Wolfer DP, Nitsch RM, Götz J (2006) Impaired reference memory and increased exploratory behavior in P301L tau transgenic mice, Genes, Brain Behav. 5:369-379, [IF 3.505] (67 cit.)
  123. Schild A, Schmidt K, Lim Y-A, Ke Y, Ittner LM, Hemmings BA, Götz J (2006) Altered levels of PP2A regulatory B/PR55 isoforms indicate role in neuronal differentiation, Int J Dev Neurosci. 24: 437-443, [IF 2.918] (26 cit.)
  124. Pennanen L, Götz J (2005) Different tau epitopes define Aβ42-mediated tau insolubility, Biochem. Biophys. Res. Commun. 337:1097-101, [IF 2.281] (33 cit.)
  125. David D, Hauptmann S, Scherping I, Schuessel K, Keil U, Dröse S, Brandt U, Müller WE, Eckert A, and Götz J (2005) Proteomic and functional analysis reveal a mitochondrial dysfunction in P301L tau transgenic mice, J. Biol. Chem. 280: 23802-23814 [selected for Faculty of 1000 Biology], [IF 4.600] (226 cit.)
  126. Götz J, Ittner LM, David DC (2005) Role of the protein tau in Alzheimer’s disease, Drug Disc. Today: Dis. Mech. 2: 395-400, [IF 5.964] (2 cit.)
  127. Hoerndli F, David D, Götz J (2005) Application of functional genomics to neurodegenerative disorders. Part II, Application and data integration, Prog. Neurobiol. 76: 169-188, [IF 10.301] (39 cit.)
  128. David D, Hoerndli F, Götz J (2005) Application of functional genomics to neurodegenerative disorders. Part I, Transcriptomic and proteomic technology, Prog. Neurobiol. 76: 153-168, [IF 10.301] (37 cit.)
  129. Hoerndli F, Toigo M, Schild A, Götz J, Day P (2004) Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative PCR, Anal. Biochem. 335: 30-41, [IF 2.305] (68 cit.)
  130. Götz J, Schild A, Hoerndli F, Pennanen L (2004) Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models, Int. J. Dev. Neurosci. 22: 453-465, [IF 2.918] (115 cit.)
  131. Chen F, Wollmer A, Hoerndli F, Münch G, Kuhla B, Rogaev EI, Tsolaki M, Papassotiropoulos A, Götz J (2004) Role for glyoxalase I in Alzheimer’s disease, PNAS 101: 7687-7692, [IF 9.809] (141 cit.)
  132. Chen F, David D, Ferrari A, Götz J (2004) Posttranslational modifications of tau – Role in human tauopathies and modelling in transgenic animal models, Current Drug Targets 5: 503-515, [IF 3.597] (92 cit.)
  133. Rauer M, Götz J, Schuppli D, Staeheli P, Hausmann J (2004) Transgenic mice expressing the nucleoprotein of Borna disease virus (BDV) in neurons and astrocytes have decreased susceptibility to homotypic infection and BDV-induced disease, J. Virol. 78: 3621-3632, [IF 4.648] (22 cit.)
  134. Götz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P, Chen F (2004) Transgenic animal models of Alzheimer’s disease and related disorders: Histopathology, behavior and therapy, Mol. Psychiatr. 9: 664-683 [cover image][recommended by AlzForum], [IF 15.147] (237 cit.) : A recent review published in Molecular Psychiatry (2004), for example, has been commented by Dr. Rachael Neve, an Alzheimer Research Forum (ARF) Adviser, as follows: “Want a summary of the main findings obtained from transgenic models of Alzheimer’s disease? This is the review to go. I like it because it’s neither too superficial nor too detailed (in which case you lose the forest for the trees). It’s also very well written and well organized: because of its good organization, you can use it as a reference to look up specific aspects of this sub-field in which you are interested. Definitely a must-read.”
  135. Pennanen L, Welzl H, D’Adamo P, Nitsch RM, Götz J (2004) Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice, Neurobiol. Dis. 15: 500-509, [IF 5.202] (73 cit.)
  136. Martens E, Stevens I, Janssens V, Vermeesch J, Götz J, Goris J, van Hoof C (2004) Genomic organization, chromosomal localization, tissue distribution and developmental regulation of the PR61/B’ regulatory subunits of Protein Phosphatase 2A in mice, J. Mol. Biol. 336: 971-986, [IF 3.959] (46 cit.)
  137. Ferrari A, Hoerndli F, Baechi T, Nitsch RM, Götz J (2003) β-Amyloid induces PHF-like tau filaments in tissue culture, J. Biol. Chem. 278, 40162-40168, [IF 4.600] (165 cit.)
  138. Kins S, Kurosinski P, Nitsch RM, Götz J (2003) Activation of the ERK and JNK signaling pathways caused by neuron specific inhibition of PP2A in transgenic mice, Am. J. Pathol. 163: 833-843, [IF 4.602] (137 cit.)
  139. Streffer JR, Papassotiropoulos A, Kurosinski P, Signorell A, Wollmer MA, Tsolaki M, Iakovidou V, Hörndli F, Bosset J, Götz J, Nitsch RM, Hock C (2003) Saitohin gene is not associated with Alzheimer’s disease, J. Neurol. Neurosur. Ps. 74: 362-363, [IF 5.580] (19 cit.)
  140. Flechsig E, Hegyi I, Leimeroth R, Zuniga A, Rossi D, Cozzio A, Schwarz P, Rülicke R, Götz J, Aguzzi A, Weissmann C (2003) Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia, EMBO J. 22: 3095-3101, [IF 10.748] (79 cit.)
  141. Götz J, Schild A (2003) Protein phosphatases: Transgenic and knockout models of PP2A, Methods Enzymol. 366: 390-403, [IF 2.194] (31 cit.)
  142. Kurosinski P, Guggisberg M, Götz J (2002) Alzheimer’s disease and Parkinson’s disease – overlapping or synergistic pathologies? (Research News), Trends Mol. Med. 8: 3-5, [IF 10.110] (48 cit.)
  143. Schmidt K, Kins S, Schild A, Nitsch RM, Hemmings B, Götz J (2002) Diversity, developmental regulation and distribution of murine PR55/B subunits of protein phosphatase 2A, Eur. J. Neurosci. 16: 2039-2048, [IF 3.669] (55 cit.)
  144. Kurosinski P, Götz J (2002) Glial cells under physiologic and pathologic conditions (Basic science seminar in neurology), Arch. Neurol. 59: 1524-1528, [IF 7.008] (78 cit.)
  145. Götz J, Chen F, Nitsch RM (2001) Interactions of beta-amyloid with the formation of neurofibrillary tangles in transgenic mice. In: Mapping the Progress of Alzheimer’s and Parkinson’s Disease (editors: Y.Mizuno, A. Fisher, I. Hanin; Kluver Academic/Plenum Publishers) Adv. in Beh. Biol. 51: 139-144, [IF: N.A.]
  146. Kins S, Crameri A, Evans DRH, Hemmings BA, Nitsch RM, Götz J (2001) Reduced PP2A activity induces abnormal phosphorylation and compartmentalization of tau in transgenic mice, J. Biol. Chem. 276: 38193-38200, [IF 4.600] (204 cit.)
  147. Götz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta42 fibrils, Science 293: 1491-1495 [discussed in a Perspectives article: Lee VM-Y (2001) Tauists and βaptists united – Well almost!, Science 293: 1446-1447] [selected for Faculty of 1000 Biology], [IF 31.477] (1,201 cit.)
  148. Götz J (2001) Tau be or not tau be – Tauopathien und transgene Tiermodelle, Neuroforum, 3/01: 93-101, [IF: N.A.]
  149. Götz J, Chen F, Barmettler R, Nitsch RM (2001) Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276: 529-534, [IF 4.600] (384 cit.)
  150. Götz J, Nitsch RM (2001) Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice, Neuroreport 12: 2007-2016, [IF 1.644] (42 cit.)
  151. Götz J, Tolnay M, Barmettler R, Chen F, Probst A, Nitsch RM (2001) Oligodendroglial tau filament formation in transgenic mice expressing G272V tau, Eur. J. Neurosci. 13: 2131-2140, [IF 3.669] (99 cit.)
  152. Götz J (2001) Tau and transgenic animal models, Brain Res. Rev. 35: 266-286, [IF 5.930] (168 cit.)
  153. Ferrari A, Ehler E, Nitsch RM, Götz J (2000) Immature human NT2 cells grafted into mouse brain differentiate into neuronal and glial cell types. FEBS Letters 486: 121-125, [IF 3.341] (66 cit.)
  154. Probst A, Götz J, Wiederhold KH, Tolnay M, Mistl C, Jaton AL, Hong M, Ishihara T, Lee VM-Y, Trojanowski JQ, Jakes R, Crowther RA, Spillantini MG, Bürki K, Goedert M (2000) Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol. 99: 469-481, [IF 11.360] (312 cit.)
  155. Götz J, Tolnay M, Barmettler R, Ferrari A, Bürki K, Goedert M, Probst A, Nitsch RM (2000) Human tau transgenic mice. Towards an animal model for neuro- and glialfibrillary lesion formation. Adv. Exp. Med. Biol. 487: 71-83, [IF 2.012] (14 cit.)
  156. Götz J, Barmettler R, Ferrari A, Goedert M, Probst A, Nitsch RM (2000) Molecular basis of dementia: In vivo analysis of wild-type and FTDP-17 tau mutant mice. Ann. N.Y.Acad. Sci. 920: 126-133, [IF 4.039] (23 cit.)
  157. Götz J, Probst A, Mistl C, Nitsch RM, Ehler E (2000) Distinct role of protein phosphatase 2A subunit Cα in the regulation of E-cadherin and β-catenin during development. Mech. Dev. 93: 83-93, [IF 2.238] (76 cit.)
  158. Götz J, Kues W (1999) The role of protein phosphatase 2A catalytic subunit Cα in embryogenesis: Evidence from sequence analysis and localization studies. Biol. Chem. 380: 1117-1120 [cover image], [IF 2.689] (17 cit.)
  159. Götz J, Probst A, Ehler E, Hemmings B, Kues W (1998) Delayed embryonic lethality in mice lacking protein phosphatase 2A catalytic subunit Cα. PNAS 95: 12370-12375, [IF 9.809] (212 cit.)
  160. Shmerling D, Hegyi I, Fischer M, Blättler T, Brandner T, Götz J, Rülicke T, Flechsig E, Cozzio A, von Mering C, Hangartner C, Aguzzi A, Weissmann C (1998) Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 93: 203-214, [IF 33.116] (507 cit.)
  161. Li ZW, Stark G, Götz J, Rülicke T, Müller U, Weissmann C (1996) Generation of mice with a 200-kb amyloid precursor protein gene deletion by Cre recombinase-mediated site-specific recombination in embryonic stem cells. PNAS 93: 6158-6162, [IF 9.809] (148 cit.)
  162. Goedert M, Spillantini MG, Jakes R, Crowther RA, Vanmechelen E, Probst A, Götz J, Bürki K, Cohen P (1995) Molecular dissection of the paired helical filament. Neurobiology of Aging 16: 325-334, [IF 4.853] (90 cit.)
  163. Goedert M, Jakes R, Spillantini MG, Crowther RA, Cohen P, Vanmechelen E, Probst A, Götz J, Bürki K (1995) Tau protein in Alzheimer's disease. Biochem. Soc. Transact. 23: 80-85, [IF 3.238] (31 cit.)
  164. Götz J, Probst A, Spillantini MG, Schäfer T, Jakes R, Bürki K, Goedert M (1995) Somatodendritic localisation and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J. 14: 1304-1313, [IF 10.748] (383 cit.)
  165. Hebert JM, Rosenquist T, Götz J, Martin GR (1994) FGF5 as a regulator of the hair growth cycle: Evidence from targeted and spontaneous mutations. Cell 78: 1017-1025, [IF 33.116] (514 cit.)
  166. Götz J, Eibel H, Köhler G (1990) Non-tolerance and differential susceptibility to diabetes in transgenic mice expressing major histocompatibility class II genes on pancreatic beta cells. Eur. J. Imm. 20: 1677-1683, [IF 4.518] (22 cit.)
  167. Cho KWY, Götz J, Fritz A, Hardwicke J, DeRobertis, EM (1988) Differential utilization of the same reading frame in a Xenopus homeobox gene encodes two related proteins sharing the same DNA-binding specificity. EMBO J. 7: 139-149, [IF 10.748] (124 cit.)

    Book Chapters and other contributions

  168. Götz J, Büttner S (2011) Stem cell therapy in Alzheimer’s disease models: neurogenesis versus trophic support, in: Frontiers in pluripotent stem cells research and therapeutic potentials. Chapter 15, Bench-to-Bedside, Ed. K Sidhu (Bentham Publishers)
  169. Götz J, Schonrock N, Vissel B, Ittner LM (2010) Alzheimer’s disease selective vulnerability and modelling in transgenic mice, in J Alzheimers Dis Handbook ‘Animal Models of Alzheimer’s Disease’
  170. Götz J, Ittner LM, Götz NN, Lam H, Nicholas H (2011) RSC (The Royal Society of Chemistry) Drug Discovery Series, Animal Models for Neurodegenerative Disease, ‘Invertebrate and vertebrate models of tauopathies’, Edited by Jesús Avila, Jose J Lucas and Félix Hernández (ISBN-10: 1849731845) 6: 69-85
  171. Götz J, David DC, Ittner L (2007) Impact of β-amyloid on the tau pathology in tau transgenic mouse and tissue culture models (chapter 12/16). In: Celebrating a Century of Research. Abeta Peptide and Alzheimer’s Disease (editors: Colin C. Barrow and David H. Small, Springer-Verlag London Ltd.), ISBN-13: 978-1-85233-961-6
  172. Götz J, Chen F (2006) Glyoxalase I and Alzheimer’s disease (chapter 10). In: Research Progress in Alzheimer’s Disease and Dementia (editor: M.-K. Sun; Nova Science Publishers, Inc., New York), ISBN 1-59454-949-4
  173. Chen F, Ferrari A, Schild A, Kurosinski P, David D, Hoerndli F, Pennanen L, Kins S, van Dorpe J, Nitsch RM, Götz J (2003) Amyloid-induced neurofibrillary tangle formation. In: Alzheimer’s disease and related disorders: Research advances (editors: K. Iqbal, B. Winblad; Ana Aslan International Foundation), p. 343-354 (chapter 30)
  174. Götz J (2002) Die Alzheimer’sche Krankheit: Wechselwirkung zwischen Tau und β-Amyloid, Festschrift aus Anlass der Verleihung des Georg Friedrich Götz-Preises 2002, p. 1-17
  175. Goedert M, Spillantini MG, Jakes R, Crowther RA, Cohen P, Vanmechelen E, Probst A, Götz J, Bürki K (1995) Molecular dissection of the paired helical filament. In: Recent Advances in Alzheimer's Disease and Related Disorders (K.Iqbal, J.Mortimer, B.Winblad & H.Wisniewski,eds). Wiley and Sons, chapter 54: 493-502


  176. SUSing approach: Neurodegenerative disease treatment, PCT/AU2015050345 (Götz J, Leinenga G)
  177. US Patent 20,150,017,657, Assay and method for identifying compounds that inhibit excitotoxic signals (L.M. Ittner, J. Götz)
  178. APPA2009904998 (PCT), Cell culture device and method (L. Ittner, T. Fath, J. Götz, Y. Ke)
  179. WO/2009/143556 (PCT/AU2009/000608): Treatments for excitotoxicity and Abeta-mediated toxicity and age-associated neuronal dysfunction (J. Götz, L. Ittner)
  180. WO 2004/017072 (PCT/EP2003/008983): A cellular assay system for neurofibrillary tangle formation (J. Götz, R. Nitsch, A. Ferrari)
  181. WO 03/017918 A2 (PCT/EP02/09491), US 07550648: A method of inducing the formation of neurofibrillary tangles in transgenic animals (J. Götz, R. Nitsch, F. Chen)